104 related articles for article (PubMed ID: 3752949)
1. Effects of aminoglutethimide plus hydrocortisone on the genital tract of postmenopausal women with advanced breast cancer. A clinical and cytologic survey.
Budel VM; Paridaens RJ; Spetschinsky A; Heuson JC; Gompel C
Anticancer Res; 1986; 6(4):709-12. PubMed ID: 3752949
[TBL] [Abstract][Full Text] [Related]
2. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen and aminoglutethimide in advanced breast cancer.
Corkery J; Leonard RC; Henderson IC; Gelman RS; Hourihan J; Ascoli DM; Salhanick HA
Cancer Res; 1982 Aug; 42(8 Suppl):3409s-3414s. PubMed ID: 7044523
[TBL] [Abstract][Full Text] [Related]
4. [Aminoglutethimide and aminoglutethimide+tamoxifen treatment for advanced breast cancer].
Hisamatsu K; Nomura Y; Tashiro H
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2017-23. PubMed ID: 1417009
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
[TBL] [Abstract][Full Text] [Related]
6. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
Harvey HA; Lipton A; White DS; Santen RJ; Boucher AE; Shafik AS; Dixon RJ
Cancer Res; 1982 Aug; 42(8 Suppl):3451s-3453s. PubMed ID: 6177405
[TBL] [Abstract][Full Text] [Related]
7. Management of breast cancer.
Cohen IA; Keller JH; Abate MA
Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
9. Antiestrogen treatment of breast cancer: an overview.
Pearson OH; Manni A; Arafah BM
Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
[TBL] [Abstract][Full Text] [Related]
10. Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer.
Mercer PM; Ebbs SR; Fraser SC; Coltart RS; Bates T
Eur J Surg Oncol; 1993 Jun; 19(3):254-8. PubMed ID: 8314383
[TBL] [Abstract][Full Text] [Related]
11. [The effects of tamoxifen on the female genital tract].
Mourits MJ; van der Zee AG; Willemse PH; Hollema H; de Vries EG
Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2315-20. PubMed ID: 14669536
[TBL] [Abstract][Full Text] [Related]
12. Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen.
Lahti E; Vuopala S; Kauppila A; Blanco G; Ruokonen A; Laatikainen T
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):410-4. PubMed ID: 7835781
[TBL] [Abstract][Full Text] [Related]
13. Aminoglutethimide as second line endocrine therapy in advanced breast cancer.
Brufman G; Biran S
Anticancer Res; 1986; 6(5):1065-8. PubMed ID: 3800315
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
[TBL] [Abstract][Full Text] [Related]
15. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin.
Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
Cancer Chemother Pharmacol; 2008 May; 61(6):933-41. PubMed ID: 17668211
[TBL] [Abstract][Full Text] [Related]
16. Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Harris AL; Cantwell BM; Sainsbury JR; Needham G; Evans RG; Dawes PJ; Wilson R; Farndon J
Breast Cancer Res Treat; 1986; 7 Suppl():S41-4. PubMed ID: 3742063
[TBL] [Abstract][Full Text] [Related]
17. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
18. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
19. Clinical studies with aminoglutethimide in advanced breast carcinoma.
Harvey HA; Lipton A; Santen RJ
Acta Clin Belg Suppl; 1986; 11():29-40. PubMed ID: 3459321
[No Abstract] [Full Text] [Related]
20. [Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast].
Bonneterre J; Pion JM; Demaille A
Bull Cancer; 1987; 74(3):241-7. PubMed ID: 3304478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
